Canada approves the Zepbound KwikPen, the first multi-dose tirzepatide pen
Canada launched a new Zepbound pen for weight loss in July 2025, months ahead of any similar US product, giving Canadian patients earlier access to a device version of tirzepatide.
Eli Lilly Canada announced on July 9, 2025, that ZEPBOUND KwikPen (tirzepatide injection) is now available in Canada for adults living with obesity or overweight [1]. Health Canada authorized the product on May 13, 2025, making it the first and only Health Canada-approved treatment that activates both the GIP and GLP-1 hormone receptors for chronic weight management [1].
The approval covers adults with a body mass index (BMI) of 30 kg/m2 or greater, or a BMI of 27 kg/m2 to under 30 kg/m2 with at least one weight-related condition, such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease [1]. It is meant to be used along with a reduced-calorie diet and increased physical activity, not as a stand-alone treatment [1].
The Canadian approval rests on results from four phase 3 studies, SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, and SURMOUNT-4, which together enrolled more than 5,000 people with obesity or overweight, with or without type 2 diabetes [1]. In SURMOUNT-1, a 72-week study of 2,539 adults with obesity or excess weight and weight-related conditions other than diabetes, people taking the highest dose (15 mg) lost an average of 21.8 kg (48 lbs.), those on the lowest dose (5 mg) lost an average of 15.4 kg (34 lbs.), and the placebo group lost an average of 3.2 kg (7 lbs.) [1].
Lilly Canada's press release does not give details on how many weekly doses the KwikPen holds or spell out a timeline for a similar multi-dose pen in the United States [1]. Those specifics are not yet known from the available information, and readers should not assume the Canadian pen and any future US device work the same way until more detail is confirmed.
Why it matters for patients
For now, this is a Canada-only development. Canadian patients gained access to a new injector device option for tirzepatide, the same active ingredient sold as Mounjaro and Zepbound, on top of the single-dose pens and vials already used elsewhere [1]. Lilly Canada's General Manager and President, Mathilde Merlet, said the company aims "to transform how this disease can be managed" through the new option [1].
Obesity affects roughly one in three Canadians, according to Statistics Canada data cited in the release, and is linked to more than 200 weight-related health conditions [1]. Physicians quoted in the announcement, including Dr. Sean Wharton and Dr. Yves Robitaille, described the approval as expanding treatment options and adding a new tool for managing obesity and its related conditions [1]. Advocacy groups, including Obesity Canada and Obesity Matters/Parlons Obésité, called for equitable access to the treatment regardless of a patient's income or insurance status [1].
US patients using Zepbound today are not affected by this specific approval, since it applies to the Canadian market and Health Canada's regulatory process [1]. Whether or when a comparable device becomes available in the United States, and what it might look like, is not addressed in this source and remains to be confirmed through separate US regulatory action.
What happens next
The source does not include any dated milestones for a US filing or clearance of a similar multi-dose pen. Patients and clinicians in the United States who want to know about future device changes for Zepbound will need to watch for separate announcements from Eli Lilly or the FDA, since none of the confirmed facts here describe US plans or dates [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.